is the average length of time IBS-C sufferers reported using OTC laxatives
of patients with IBS-C reported being “very satisfied” with their OTC laxatives†
The ACG Guideline suggests against the use of2:
ACG, American College of Gastroenterology; CIC, chronic idiopathic constipation; IBS-C, irritable bowel syndrome with constipation; OTC, over the counter; PEG, polyethylene glycol.
*Data from an online survey commissioned by Ironwood Pharmaceuticals, Inc. and Allergan in 2018. 501 patients with IBS-C and 610 patients with CIC qualified for the detailed survey after meeting ROME IV criteria for IBS-C or CIC.1
†In this survey of IBS-C sufferers taking OTC laxatives, 16% were “very satisfied,” 44% were “somewhat satisfied,” 22% were “neither satisfied nor dissatisfied,” 11% were “somewhat dissatisfied,” and 7% were “very dissatisfied.”1
‡The strength of the recommendation is given as conditional if many patients should have this recommended course of action, but different choices may be appropriate for some patients.2
§Due to the low and very low quality of evidence, the estimate of effect is very uncertain.2
||The ACG Guideline does not clearly define “global IBS symptoms.”
¶Not actual patients. For illustrative purposes only.
Please see full Prescribing Information, including Boxed Warning, or visit https://www.rxabbvie.com/pdf/linzess_pi.pdf.
US-LIN-230215
References: 1. Data on file. Allergan, Inc. 2. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
